LILOPRISTONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H37NO3
Molecular Weight	447.609
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@@](O)(\C=C/CO)[C@@]1(C)C[C@H](C3=CC=C(C=C3)N(C)C)C4=C5CCC(=O)C=C5CC[C@@]24[H]

InChI

InChIKey=RCOWGILQXUPXEW-FUSOFXSQSA-N

InChI=1S/C29H37NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h4-6,8-9,14,17,24-26,31,33H,7,10-13,15-16,18H2,1-3H3/b14-4-/t24-,25+,26-,28-,29-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800008704 | https://www.ncbi.nlm.nih.gov/pubmed/15774087 | https://www.ncbi.nlm.nih.gov/pubmed/2502015

Lilopristone (ZK 98.734) has a high affinity for progesterone receptors. The progesterone antagonistic effects of ZK 98.734 could be a result of the decrease in progesterone synthesis by the corpus luteum and/or placenta in addition to the interference with the progesterone binding to its cellular receptors in the target organ. ZK 98.734 has potential for fertility regulation. It is a very potent abortifacient in the common marmosets. Lilopristone could significantly suppress the proliferation of ectopic stromal cells in a time- and dose-dependent manner in vitro. The action mechanisms may be associated with the suppression of expression of NF-kappaB P65 mRNA and NF-kappaB P65.

Approval Year

PubMed

Title	Date	PubMed
Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone.	1997 Oct	9321513

Sample Use Guides

In Vivo Use Guide

Single dose of 5 mg in 0.2 ml of the vehicle

Route of Administration: Intramuscular

Name

Type

Language

LILOPRISTONE

Official Name

English

lilopristone [INN]

Common Name

English

11.BETA.-(P-(DIMETHYLAMINO)PHENYL)-17.BETA.-HYDROXY-17-((Z)-3-HYDROXYPROPENYL)ESTRA-4,9-DIEN-3-ONE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1891